PSI
LCTX icon

Pinnacle Summer Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Pinnacle Summer Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$1K Hold
186
– – ﹤0.01% 736
2015
Q3 		$1K Hold
186
– – ﹤0.01% 951
2015
Q2 		$1K Hold
186
– – ﹤0.01% 712
2015
Q1 		$1K Hold
186
– – ﹤0.01% 971
2014
Q4 		$1K Hold
186
– – ﹤0.01% 987
2014
Q3 		$0 Hold
186
– – ﹤0.01% 1079
2014
Q2 		$0 Hold
186
– – ﹤0.01% 1019
2014
Q1 		$0 Hold
186
– – ﹤0.01% 992
2013
Q4 		$1K Hold
186
– – ﹤0.01% 927
2013
Q3 		$1K Hold
186
– – ﹤0.01% 900
2013
Q2 		$1K Buy
+186
New +$596 ﹤0.01% 798

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Summer Investments's LCTX Position: Q4 2015 in Review

Pinnacle Summer Investments held its Lineage Cell Therapeutics (LCTX) position steady in Q4 2015 at 186 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #736.

Pinnacle Summer Investments first reported a position in LCTX in Q2 2013 and has held it in 11 quarters since. 68 funds tracked by Wall St. Rank hold LCTX as of Q4 2015.

  • Pinnacle Summer Investments held 186 shares of Lineage Cell Therapeutics worth $1K as of Q4 2015.
  • Pinnacle Summer Investments left its Lineage Cell Therapeutics share count unchanged in Q4 2015.
  • Lineage Cell Therapeutics made up ﹤0.01% of Pinnacle Summer Investments's portfolio in Q4 2015, its #736 holding.
  • Pinnacle Summer Investments first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 11 quarters since.
  • 68 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2015.

Based on Pinnacle Summer Investments's 13F filing for Q4 2015, filed 16 Feb 2016.